← Holders
Logos Global Management LP
What Logos Global Management LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1792126 · Filed Nov 16, 2026
- Positions
- 72
- Reported value
- $1.9B
- Opened
- 29
- Closed
- 25
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$1.1B59 positions
- Dec 31, 2025$1.7B69 positions
- Mar 31, 2026$2B66 positions
- Jun 30, 2026$2.3B68 positions
- Sep 30, 2026$1.9B72 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
PRAXPraxis Precision Medicines, Inc. | 425K | +63.5% | $123.8M | 6.7% |
RVMDRevolution Medicines, Inc. | 600K | −14.3% | $123.2M | 6.6% |
IDYAIDEAYA Biosciences, Inc. | 2.9M | −5.0% | $109.5M | 5.9% |
ERASErasca, Inc. | 5.9M | −51.4% | $86.5M | 4.7% |
ABVXAbivax S.A. | 870K | −15.0% | $86.1M | 4.6% |
CGONCG Oncology, Inc. | 975K | −2.5% | $69.1M | 3.7% |
IRONDisc Medicine, Inc. | 1M | +16.0% | $66.4M | 3.6% |
BNTXBioNTech SE | 650K | −36.0% | $63.9M | 3.4% |
TNGXTango Therapeutics, Inc. | 2.2M | −24.6% | $53.6M | 2.9% |
MDGLMadrigal Pharmaceuticals, Inc. | 100K | New | $50.4M | 2.7% |
ELVNEnliven Therapeutics, Inc. | 1.1M | +132.3% | $49.5M | 2.7% |
DYNDyne Therapeutics, Inc. | 3M | +17.6% | $48.3M | 2.6% |
OCULOcular Therapeutix, Inc | 6M | +13.2% | $46M | 2.5% |
DNTHDianthus Therapeutics, Inc. | 500K | −37.5% | $44M | 2.4% |
AVBPArriVent BioPharma, Inc. | 1.4M | +35.0% | $40.9M | 2.2% |
COGTCogent Biosciences, Inc. | 1.3M | +38.9% | $40M | 2.2% |
| 2.5M | New | $36.7M | 2% | |
NBIXNeurocrine Biosciences Inc | 250K | New | $35.5M | 1.9% |
BLTEBelite Bio, Inc | 200K | −20.0% | $34M | 1.8% |
AXSMAxsome Therapeutics, Inc. | 175K | New | $32.3M | 1.7% |
GPCRStructure Therapeutics Inc. | 1M | +100.0% | $31.3M | 1.7% |
OLMAOlema Oncology, Inc. | 3.2M | ±0% | $27.7M | 1.5% |
ACHVAchieve Life Sciences, Inc. | 3.2M | −41.0% | $25.9M | 1.4% |
MAZEMaze Therapeutics, Inc. | 935K | −51.7% | $25.4M | 1.4% |
PBLSParabilis Medicines, Inc. | 750K | +42.9% | $24.2M | 1.3% |
APMDApnimed, Inc. | 1.1M | New | $24.1M | 1.3% |
YARWYarrow Bioscience, Inc. | 1M | New | $23.1M | 1.2% |
| 1.5M | New | $23M | 1.2% | |
TRVITrevi Therapeutics, Inc. | 1.4M | −23.1% | $20.7M | 1.1% |
MANEVeradermics, Inc | 170K | −5.6% | $20.6M | 1.1% |
| 1.5M | New | $19.9M | 1.1% | |
VERAVera Therapeutics, Inc. | 600K | −72.7% | $19.4M | 1% |
| 1.5M | New | $18.9M | 1% | |
SRPTSarepta Therapeutics, Inc. | 1M | New | $18.2M | 1% |
| 1M | New | $18.2M | 1% | |
MLTXMoonLake Immunotherapeutics | 1.5M | −43.9% | $17.6M | 0.9% |
| 1M | New | $16.9M | 0.9% | |
IMCRImmunocore Holdings plc | 500K | −16.7% | $15.1M | 0.8% |
BHVNBiohaven Ltd. | 1.1M | New | $14.7M | 0.8% |
CRSPCRISPR Therapeutics AG | 250K | −16.7% | $13.8M | 0.7% |
| 1M | New | $13.4M | 0.7% | |
DFTXDefinium Therapeutics, Inc. | 350K | +337.5% | $13.3M | 0.7% |
| 500K | New | $12.9M | 0.7% | |
ENTXEntera Bio Ltd. | 4.4M | New | $12.8M | 0.7% |
DSGNDesign Therapeutics, Inc. | 1M | −66.7% | $12.6M | 0.7% |
| 1M | New | $12.4M | 0.7% | |
CBIOCrescent Biopharma, Inc. | 850K | −55.3% | $12.4M | 0.7% |
ETRAElectra Therapeutics, Inc. | 1M | New | $11.3M | 0.6% |
NERVMinerva Neurosciences, Inc. | 3.3M | ±0% | $11M | 0.6% |
LBRXLB Pharmaceuticals Inc | 250K | −57.3% | $9.6M | 0.5% |
| 1M | New | $8.1M | 0.4% | |
| 1M | New | $7.4M | 0.4% | |
| 2M | New | $7.4M | 0.4% | |
| 2M | New | $6.5M | 0.4% | |
VKTXViking Therapeutics, Inc. | 200K | New | $6.5M | 0.4% |
EDITEditas Medicine, Inc. | 2.2M | ±0% | $5.7M | 0.3% |
TNXPTonix Pharmaceuticals Holding Corp. | 550K | New | $5.4M | 0.3% |
IRDOpus Genetics, Inc. | 1M | New | $4.8M | 0.3% |
VOGXVogenx, Inc. | 205K | New | $4.7M | 0.3% |
IMVTImmunovant, Inc. | 85K | −87.2% | $2.9M | 0.2% |
JBIOJade Biosciences, Inc. | 200K | −82.2% | $2.8M | 0.2% |
OKUROnKure Therapeutics, Inc. | 963.9K | ±0% | $2.6M | 0.1% |
TCGXTCGX Acquisition Corp. | 200K | New | $2.5M | 0.1% |
UNCYUnicycive Therapeutics, Inc. | 473.6K | ±0% | $2.2M | 0.1% |
PTNPalatin Technologies Inc | 129.3K | −0.6% | $1.1M | 0.1% |
JATTJATT II Acquisition Corp. | 100K | ±0% | $1.1M | 0.1% |
JTTTJATT III Acquisition Corp | 100K | New | $1.1M | 0.1% |
RACCResearch Alliance Corp III | 100K | ±0% | $1.1M | 0.1% |
SEPNSepterna, Inc. | 23.5K | ±0% | $921.4K | 0.1% |
AMANAmanat Acquisition Corp. | 50K | ±0% | $534K | 0.1% |
LGVNLongeveron Inc. | 192.3K | New | $517.3K | 0.1% |
GUTSFractyl Health, Inc. | 505K | −49.5% | $274.9K | 0.1% |